Market Overview - The Hong Kong stock market opened lower on December 3, with the Hang Seng Index down 0.44% at 25,980.89 points, the Hang Seng Tech Index down 0.51% at 5,595.53 points, the National Enterprises Index down 0.55% at 9,132.53 points, and the Red Chip Index down 0.24% at 4,267.46 points [1] - Major tech stocks mostly declined, with Alibaba down 0.76%, Tencent Holdings down 0.16%, JD.com down 0.34%, NetEase down 1.52%, Kuaishou down 1.38%, and Bilibili down 1.08% [1] - Automotive stocks continued to diverge, with NIO and Xpeng Motors declining, while gambling stocks, food and beverage stocks, and the three major oil companies also saw declines [1] - Nuclear power stocks, building materials and cement stocks, and new consumption concept stocks mostly rose, with new stock Jinyan Gaoling New Materials opening over 27% higher [1] Corporate News - Hezhima Intelligent (02533.HK) plans to invest approximately 400-550 million yuan to acquire a majority stake in Zhuhai Yizhi Electronic Technology Co., expecting the acquisition to be completed in Q1 2026 [2] - China Qinfa (00866.HK) signed a coal supply agreement with Zhejiang Energy Asia Pacific to provide 150,000 tons of Indonesian fuel coal [2] - Fuhong Hanlin (02696.HK) received acceptance for the listing registration application of its biosimilar HLX14, with global sales of similar products expected to reach approximately $7.463 billion in 2024 [2] - Deki Pharmaceuticals-B (06996.HK) received IND approval for its IB/II phase study of ATG-022 in combination with KEYTRUDA® (pembrolizumab) ± chemotherapy in China [2] - Gakosi-B (01167.HK) received a down payment of 125 million yuan from Haicong Capital as part of its capital increase and share transfer agreement, which will support the development of its innovative oncology therapy pipeline [2] Stock Buybacks - Tencent Holdings (00700.HK) repurchased approximately 1.036 billion HKD worth of shares, buying back 1.028 million shares at prices between 615.5 and 625.5 HKD [6] - Xiaomi Group-W (01810.HK) repurchased shares worth 102 million HKD, buying back 2.5 million shares at prices between 40.5 and 40.72 HKD [7] - China Feihe (06186.HK) repurchased shares worth 16.74 million HKD, buying back 4 million shares at prices between 4.17 and 4.20 HKD [8] - COSCO Shipping Holdings (01919.HK) repurchased shares worth 41.053 million HKD, buying back 3 million shares at prices between 13.62 and 13.81 HKD [9] - Jiuyuan Gene (02566.HK) plans to repurchase shares up to 100 million HKD [10] Institutional Insights - Guoyuan International noted uncertainty in the direction of the Federal Reserve's decisions in December, influenced by recent economic data and Japan's hawkish stance, suggesting potential external disturbances for the Hong Kong market [11] - Zhongtai Securities highlighted a new cycle for coal, recommending investment opportunities in the coal sector for 2026, focusing on three main lines: high dividend and low valuation stocks, companies with capacity growth and significant profit elasticity, and coking coal benefiting from price recovery and profit improvement [11]

Group 1: Federal Reserve Leadership and Economic Outlook - President Trump has named Kevin Hassett as a potential candidate for the next Federal Reserve Chair, with plans to announce the selection in early 2026, increasing speculation about the Fed's future leadership [1] - According to CME's FedWatch tool, there is an 89.2% probability of a 25 basis point rate cut in December, and a 66.6% probability of a cumulative 25 basis point cut by January 2024 [1] - The OECD predicts that developed economies will end their current rate-cutting cycle by the end of 2026, indicating limited policy easing space for major central banks despite potential economic slowdowns [1] Group 2: Stock Market Performance - U.S. stock markets saw gains, with the Dow Jones Industrial Average rising by 185.13 points to 47,474.46, a 0.39% increase, and the S&P 500 up by 16.74 points to 6,829.37, a 0.25% increase [2] - Apple shares rose over 1%, marking a seventh consecutive day of gains and reaching a new all-time high [2] - Chinese concept stocks mostly declined, with the Nasdaq Golden Dragon China Index falling by 0.65% [2] Group 3: Economic Growth Forecasts - The OECD has raised its 2025 economic growth forecast for China to 5%, up from a previous estimate of 4.9% [3] - Global economic growth is projected at 3.2% for 2025 and 2.9% for 2026, remaining unchanged from prior forecasts [3] Group 4: Semiconductor Market Insights - Morgan Stanley forecasts that the humanoid robot semiconductor market will reach $305 billion by 2045, with demand expected to grow by approximately 15% from 2025 to 2030, followed by a 40% increase thereafter [4] Group 5: Strategic Partnerships and Collaborations - EVE Energy has signed a comprehensive strategic cooperation agreement with China Gas, focusing on energy storage technology innovation and the large-scale application of clean energy [8] - Sunny Optical Technology is the exclusive supplier of camera lenses and main camera telephoto modules for the Doubao mobile assistant engineering prototype [6] Group 6: New Product Launches and Approvals - Xpeng Motors and Huawei jointly launched the next-generation DriveONE range extender generator, achieving a power density of 1.88 kW/kg and an industry-leading efficiency of ≥92% [5] - Daqi Pharmaceutical has received IND approval for its ATG-022 combined with KEYTRUDA® and chemotherapy in China [9] Group 7: Corporate Acquisitions and Stock Movements - JD.com has acquired approximately 59.8% of Ceconomy’s equity and voting rights, with total holdings expected to reach 85.2% after the transaction [10] - Black Sesame Intelligence plans to invest approximately RMB 400 million to 550 million to acquire a majority stake in Zhuhai Yizhi Electronics Technology [14]

Core Viewpoint - The approval of the investigational new drug (IND) application for ATG-022, a CLDN18.2 antibody-drug conjugate, in combination with MSD's KEYTRUDA® and chemotherapy, marks a significant advancement in cancer treatment research [1] Group 1: Company Developments - The China National Medical Products Administration (NMPA) has approved the IND application for ATG-022 in conjunction with KEYTRUDA® and chemotherapy [1] - The clinical study, named CLINCH-2, is an Ib/II phase trial aimed at evaluating the efficacy of the combination therapy [1]

Core Viewpoint - The approval of the investigational new drug (IND) application for ATG-022, a CLDN18.2 antibody-drug conjugate (ADC), by the National Medical Products Administration (NMPA) in China marks a significant advancement for the company in its clinical research efforts [1] Group 1 - The NMPA has approved the IND application for ATG-022 in combination with MSD's KEYTRUDA® (pembrolizumab) [1] - The approval includes the initiation of the Phase Ib/II CLINCH-2 study, which will evaluate the combination of ATG-022 with pembrolizumab and chemotherapy [1]